An observational study in Early Breast Cancer (EBC), sponsored by Spanish Breast Cancer Research Group. Recruiting at 10 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Spanish Breast Cancer Research Group · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Breast Neoplasms by Spanish Breast Cancer Research Group — 4 open to participants now, 7 under way, none of them phase 3. Breast Neoplasms · Spanish Breast Cancer Research Group.
Among the 49 studies in Breast Neoplasms by Spanish Breast Cancer Research Group, this one is the 7th largest by planned enrollment of the 14 observational ones that give a count, is one of 2 that started in 2026, is one of 14 observational ones, and was the 49th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →4 of the 49 studies in Breast Neoplasms by Spanish Breast Cancer Research Group are open now, in 1 country. Recruiting first, the newest first:
Spanish Breast Cancer Research Group · Sites in Spain
Ages 18+ · Women only
Spanish Breast Cancer Research Group · Sites in Spain
Ages 18+ · Women only
Spanish Breast Cancer Research Group · Sites in Spain
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 18 · Phase 3 12 · Phase 4 3
First in 1999; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 103 across the 35 interventional studies, 271 across the 14 observational. Of the 41 that completed or were terminated, 20 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
Spanish Breast Cancer Research Group is the lead sponsor of 50 studies on the registry; 4 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 49 studies in Breast Neoplasms by Spanish Breast Cancer Research Group, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to explore the utility of analytical techniques that enable the study of small amounts of tumor-derived material circulating in the blood, such as fragments of circulating tumor DNA (also known as ctDNA), cells, or other particles. This type of sample is generally referred to as a liquid biopsy, and its analysis is a minimally invasive test, as it only requires the collection of blood samples. The study includes women and men with early-stage breast cancer (EBC) who are about to start neoadjuvant treatment (treatment given before surgery). The main questions it aims to answer are:
Participants will:
Study Rationale:
Neoadjuvant therapy (NAT) is a standard treatment approach for patients with early-stage breast cancer (EBC), its benefits extend beyond enabling breast conserving surgery: it provides an early dynamic assessment of treatment sensitivity and creates an in vivo framework to interrogate tumor biology under therapeutic pressure. Pathological complete response (pCR) is an established surrogate marker of prognosis, particularly in triple negative (TN) and Human Epidermal Growth Factor Receptor 2(HER2)-positive breast cancer; however, the ability to predict response early during treatment and to identify patients at risk of residual disease or relapse remains limited.
Circulating tumor DNA (ctDNA) has emerged as a promising minimally invasive biomarker for monitoring tumor burden and treatment response in real time. Previous studies have shown that baseline ctDNA levels, early ctDNA clearance during NAT, and postoperative ctDNA detection are associated with treatment response, minimal residual disease (MRD), and relapse risk. Nevertheless, the clinical utility of ctDNA across breast cancer subtypes and its integration into routine clinical decision-making remain incompletely defined.
The neoAGORA study aims to evaluate subtype-specific ctDNA dynamics during standard NAT and to investigate their relationship with clinical outcomes, pathological response, advanced imaging findings, and digital pathology assessments. By integrating these complementary sources of information, the study seeks to improve response assessment and support the development of personalized management strategies for patients with EBC.
Study design:
The neoAGORA study is a multicenter observational study designed to investigate the value of liquid biopsy technologies in patients with EBC receiving standard neoadjuvant therapy. The study will include patients with luminal, HER2-positive, and TN tumors treated according to routine clinical practice.
The neoAGORA prospective cohort will systematically collect clinical data, biological samples, and imaging information throughout treatment and follow-up. Serial blood samples will be collected at predefined time points before, during, and after neoadjuvant therapy, as well as tumor samples obtained at diagnosis, during treatment when available, at surgery, and at disease relapse. In addition, detailed clinical data will be collected, including demographic and clinical characteristics, treatments administered, radiological response, pathological response, and recurrence and survival outcomes.
The study will incorporate a centralized biorepository and a common infrastructure for standardized collection of data and biological samples, enabling the evaluation of liquid biopsy-derived biomarkers, digital pathology, and advanced imaging in a real-world clinical setting.
At least 300 patients (approximately 100 per breast cancer subtype) are expected to be enrolled. The platform is designed to allow future cohort expansions and to facilitate collaborative research aimed at evaluating the clinical utility of novel biomarkers and personalized medicine strategies in EBC.
Study population and length of study:
The neoAGORA study is a continuous recruitment study that will remain open indefinitely. The first cohort will include at least 300 patients, distributed evenly across the main breast cancer tumor subtypes. Recruitment of this cohort is expected to be completed in approximately 18 months.
All participants will be followed for a minimum of 5 years after surgery. The study completion date for this cohort will be defined as the last visit of the last patient enrolled, resulting in an estimated total study duration of approximately 7 years from the inclusion of the first patient.
The target population for inclusion in this study is BC patients scheduled to receive neoadjuvant treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with a first diagnosis of the UICC (Union for International Cancer Control) stage I-III primary invasive BC whose tumors are of any of the following subtypes:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The neoAGORA prospective cohort will include patients diagnosed with Early-stage Breast Cancer with luminal, HER2-positive and Triple Negative tumors scheduled to receive Neoadjuvant Therapy. Patients will be treated according to standard clinical practice.
Other: biological samples, images, and clinical data
This is an observational study in which clinical decisions concerning the optimum therapy for a particular patient are taken independently of, and prior to, offering the patient to participate in the study. The treating physician will make all treatment decisions according to his/her regular clinical practice independent of this study. The study will systematically collect and integrate biological samples, images, and clinical data in the neoadjuvant and follow-up period. Serial blood samples are collected for neoAGORA study align with blood extractions performed as part of the patient's standard clinical care and tumor samples are residual samples from clinical practice.
Prognostic and Predictive Value of ctDNA in Patients Receiving NAT
To evaluate the association between ctDNA detection, molecular profiling, and longitudinal ctDNA dynamics (at baseline, during NAT and pre-surgery) and efficacy outcomes. The ctDNA metrics and patterns assessed before surgery will be: * ctDNA status/levels and molecular profiling at baseline, during NAT and post-NAT (pre-surgery), * early ctDNA dynamics during NAT (e.g. clearance vs. persistence), * ctDNA dynamics patterns post-NAT (pre-surgery) (e.g. clearance, persistence, rebound). Specific objectives: * To evaluate the association between the ctDNA metrics and patterns detailed in the protocol. * To derive candidate early ctDNA change thresholds during NAT and estimate their predictive and prognostic value.
Time frame: From Study Start Date to Primary Completion Date (25 months).
Prognostic and predictive value of molecular residual disease (MRD) assessed by ctDNA
To evaluate the association between post-surgery Molecular Residual Disease (MRD) and pre-surgery ctDNA status, and the correlation of post-surgery MRD with pathological residual disease at surgery, radiological response, and time-to-event efficacy outcomes.
Time frame: From Study Start Date to Study Completion Date (84 months).
Characterization of tumor evolution
To characterize tumor molecular evolution using longitudinal liquid biopsies (ctDNA, ctRNA, etc) collected at baseline, throughout NAT, and during follow-up.
Time frame: From Study Start Date to Study Completion Date (84 months).
Biomarker discovery
To identify candidate molecular biomarkers and profiles from liquid biopsies and tumor tissue that predict efficacy outcomes in early-stage disease (hypothesis-generating).
Time frame: From Study Start Date to Study Completion Date (84 months).
Reduction in the need for invasive procedures
To assess ctDNA as a minimal or non-invasive complement to tissue biopsies for tumor characterization and treatment monitoring across the early-stage disease.
Time frame: From Study Start Date to Study Completion Date (84months).
Imaging predictions of tumor response and disease relapse
To explore the ability of advanced imaging modalities and quantitative analysis (including AI-enabled tools) to accurately predict pathological response and efficacy outcomes.
Time frame: From Study Start Date to Study Completion Date (84 months). This will only be conducted if funding is obtained.
Multimodal integration: ctDNA, imaging, and digital pathology readouts
To evaluate the incremental prognostic and predictive value of ctDNA-derived metrics within an integrated multimodal framework, incorporating imaging and pathology readouts, including AI-enabled approaches.
Time frame: From Study Start Date to Study Completion Date (84 months).
Effectiveness in routine clinical practice
To explore effectiveness outcomes in specific populations often underrepresented in clinical studies (such as elderly patients, those with organ dysfunction, or those requiring dose adjustments) while also describing effectiveness outcomes across different NAT regimens within routine clinical practice that encompasses a broader and more heterogeneous population than the one typically represented in drug-register oriented clinical studies.
Time frame: From Study Start Date to Study Completion Date (84 months).
Pharmacoeconomics
To evaluate the economic impact and social value generated by incorporating ctDNA-based liquid biopsy and MRD status analysis into the care pathway of patients with EBC treated with NAT in real-world clinical practice, through the characterization of observed care trajectories, the estimation of associated costs and clinical outcomes, and the multidimensional quantification of the value generated for the patient, the healthcare system, and society as a whole.
Time frame: From Study Start Date to Study Completion Date (84 months). This will only be conducted if funding is obtained.
Plan to share: No
Started Sep 2026 (actual). Primary completion is estimated for Sep 2028, 24 months after the start.
Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 24 months is below that.
Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 8, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Spanish Breast Cancer Research Group